Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $6.40.
Several brokerages have recently commented on CNTX. Lifesci Capital downgraded shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Wall Street Zen cut shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Citigroup reissued an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Weiss Ratings upgraded shares of Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 15th. Finally, Zacks Research raised shares of Context Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday.
Check Out Our Latest Stock Report on Context Therapeutics
Institutional Inflows and Outflows
Context Therapeutics Stock Performance
CNTX opened at $0.20 on Friday. The stock’s 50 day simple moving average is $0.29 and its 200 day simple moving average is $1.38. Context Therapeutics has a 1 year low of $0.18 and a 1 year high of $3.62.
Context Therapeutics (NASDAQ:CNTX – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Analysts expect that Context Therapeutics will post -0.47 EPS for the current fiscal year.
Context Therapeutics Company Profile
Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens. Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.
Featured Articles
- Five stocks we like better than Context Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
